Bristol Touts Opdivo's Stability – And Diversity – In Strong Q2
The recently launched Opdivo/Yervoy combination already has a leading position in first-line kidney cancer in the US – with a 30% share of new patients – but has been rejected in Europe.
You may also be interested in...
Bristol says its checkpoint immunotherapies can hold the lead in renal cell carcinoma, despite increasing competition.
Merck & Co.’s IO powerhouse Keytruda has trumped Bavencio’s recent Inlyta combo PFS win in kidney cancer, with a OS and PFS combo hit of its own. But the field is getting increasingly crowded.
Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.